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Background: This study investigates whether diabetes mellitus is a risk factor for the development of papillary
thyroid cancer, using an age-, gender-, and race-matched analysis.
Methods: We retrospectively reviewed the charts of 1559 patients with newly evaluated thyroid cancer over a 4-year
period at our institution and identified 1313 patients (84%) with papillary thyroid carcinoma. Characteristics of patients
with diabetes versus those without diabetes were compared with a chi-square test for categorical variables and
the Wilcoxon Rank Sum test for numeric variables. The prevalence of diabetes among patients with papillary thyroid
carcinoma at our institution was compared (using an age-, gender-, and race-matched analysis) with that expected
based on data from the continuous National Health and Nutrition Examination Survey (NHANES) from the same time
period.
Results: For patients with papillary thyroid carcinoma, the median age was 47 years; 74% were female; 83% were
white; and the prevalence of diabetes was 8%. Among those with diabetes, 92% had type 2 diabetes, and 24% were
treated with insulin. Risk factors for diabetes included age and race. The prevalence of diabetes among patients with
papillary thyroid carcinoma of all ages versus that among patients from NHANES of all ages was not significantly
different (RR 1.07, CI 0.88 - 1.28). The prevalence of diabetes among patients with papillary thyroid cancer who were
44 years of age or younger versus that among patients from NHANES who were 44 years of age or younger, however,
was significantly increased (RR 2.32, CI 1.37 - 3.66). There was no significant difference when subgroup analysis was
performed by gender or race.
Conclusions: We found an increased prevalence of diabetes in patients with papillary thyroid carcinoma who
were 44 years of age or younger.
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Diabetes mellitus is a risk factor for cancer, specifically of
breast, endometrium, bladder, liver, colorectum, and pan-
creas [1]. The pathophysiology of how diabetes contrib-
utes to cancer growth or development is an area of active
investigation. The most commonly proposed mechanism
is that hyperinsulinemia, which results as a compensatory
response to the insulin resistance underlying type 2 dia-
betes, is mitogenic, through activation of the insulin re-
ceptor or the insulin-like growth factor-I receptor [2],
which in turn stimulates cellular proliferation and inhibits
cellular apoptosis [3]. Another possible mechanism is that* Correspondence: kalinm@mskcc.org
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unless otherwise stated.hyperglycemia promotes carcinogenesis by increasing oxi-
dative stress [1].
Several previous studies have tested for an association
between diabetes and thyroid cancer, including one case
control study and three large cohort studies. The case
control study, which comprised 110 patients with ana-
plastic thyroid cancer, found a 4-fold increased preva-
lence of diabetes [4].
In the National Institutes of Health-AARP diet and
health study, which involved a cohort of almost 500,000
adults, the prevalence of diabetes was 7.4% in women,
and 10.1% in men. Over 10 years, 585 cases of thyroid
cancer were identified. Women with diabetes had a 1.46
increased risk for all thyroid cancers, a 1.25 increased
risk for papillary thyroid cancer, and a 1.92 increasedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cant difference in the risk of thyroid cancer for men with
diabetes or for the combined group of men and women
with diabetes [5].
A cohort study of 4.5 million male veterans with 1053
cases of thyroid cancer found non-significant increases
in risk for thyroid cancer among patients with diabetes:
1.2 for less than 5 years of diabetes, and 1.1 for at least
5 years of diabetes [6].
A population-based study of 1 million patients in
Taiwan with 943 cases of thyroid cancer found no as-
sociation between diabetes and thyroid cancer; less
than 5 years of diabetes was associated with a de-
creased thyroid cancer risk [7]. In summary, the data
from previous studies differ regarding a potential asso-
ciation between diabetes and thyroid cancer.
Our study is unique in that it is the only study to focus
exclusively on patients with papillary thyroid carcinoma,
the most common type of thyroid cancer. Using an age-,
gender-, and race-matched analysis, we compared the
prevalence of diabetes in patients with papillary thyroid
carcinoma at our institution with that expected based on
data from the continuous National Health and Nutrition




A retrospective chart review was performed after approval
of an exemption from IRB/PB Review by the Memorial
Sloan-Kettering Institutional Review Board/Privacy Board
and in agreement with the principles of the Declaration of
Helsinki involving research involving human subjects. A
database was generated of all patients with newly evalu-
ated thyroid cancer at one institution, Memorial Sloan-
Kettering Cancer Center, for 4 years, from January 1,
2005, to December 31, 2008, totaling 1,559 patients. The
database included patients with thyroid carcinoma newly
diagnosed at our institution as well as patients with a prior
diagnosis of thyroid carcinoma referred from the outside.
All patients received a rigorous internal review of hist-
ology. Extracted data included age at diagnosis, gender,
race, type of thyroid cancer, diagnosis of diabetes, and an-
tidiabetic medication use at the time of papillary thyroid
carcinoma evaluation. After a diagnosis of papillary thy-
roid carcinoma as proven by pathology was reached at our
institution, a subsequent diagnosis or use of antidiabetic
medications was not included.
Of the 1559 patients identified, 8 entries were dupli-
cates; 17 patients had no primary thyroid cancer diagnosis;
and 13 patients had unknown race. These 38 patients were
excluded. We further restricted our cohort to those with
papillary thyroid carcinoma and excluded 24 patients with
anaplastic thyroid carcinoma, 40 patients with follicularthyroid carcinoma, 41 patients with Hurthle cell thyroid
carcinoma, 49 patients with medullary thyroid carcinoma,
52 patients with poorly differentiated thyroid carcinoma,
and 1 patient with minimally invasive hyalinizing trabecular
carcinoma. Of the original 1559 patients, 1313 patients with
papillary thyroid carcinoma remained for analysis (84%).
Statistical analysis
Characteristics were compared between patients with
diabetes and those without diabetes using the chi-square
test for categorical variables and the Wilcoxon Rank
Sum test for numeric variables. To determine whether
the rate of diabetes was higher than expected in the
group of patients with newly evaluated papillary thyroid
carcinoma at our institution, we compared their ob-
served prevalence of diabetes to the prevalence of dia-
betes in patients in the National Health and Nutrition
Examination Survey (NHANES). NHANES is a federal
program that seeks to assess the health and nutritional
status of adults and children in the United States and
has a publicly available data set on the Centers for Dis-
ease Control and Prevention website. We used NHANES
data for 2005–2008. The expected number of patients
with diabetes was estimated by multiplying the NHANES
rate of diabetes for each age, sex, and race subgroup by
the number of thyroid cancer patients within those sub-
groups. The observed and expected numbers of cases of
diabetes were then separately summed and the relative risk
(RR) was expressed as the ratio of observed-to-expected
cases. The 95% confidence interval was calculated based
on the assumption that the observed number of patients
with diabetes was distributed as a Poisson variable.
We analyzed patients 44 years of age or younger separ-
ately from those 45 years of age or older based on literature
suggesting that age 45 years or older is a risk factor for dia-
betes [9]. We also analyzed separately patients 65–74 years
of age and those 75 years of age or older to separate elderly
patients who practice healthy behaviors that enhance their
life span and could be protective against diabetes [10].
Results
Patient characteristics
The demographics of the patients with papillary thyroid
cancer in our cohort are listed in Table 1. The median
age at evaluation was 47 years, with a range from 3 to
91 years of age; 74% were female; 83% were white; and
8% had diabetes. Of the 110 patients with diabetes, 92%
had type 2 diabetes, and 6% had type 1 diabetes (Table 2);
24% of patients with diabetes were taking insulin.
Prevalence of diabetes in patients with papillary thyroid
cancer versus that from NHANES
Using an age-, gender-, and race-matched analysis as de-
scribed in the methods, we compared the prevalence of
Table 1 Patient characteristics
All patients
N = 1313
Age at evaluation Median (range) 47 (3–91)
0 - 44 589 (45%)
45 - 64 535 (41%)
65 - 74 143 (11%)
75+ 46 (3%)
Sex Male 347 (26%)
Female 966 (74%)









Table 3 Prevalence of diabetes in patients with newly
evaluated papillary thyroid carcinoma at our institution










All patients 110 103 1.07 0.88-1.28
By age 0-44 18 8 2.32 1.37-3.66*
45-64 61 59 1.03 0.79-1.32
65-74 23 29 0.81 0.51-1.21
75+ 8 8 1.04 0.45-2.05
By sex Male 31 31 0.99 0.67-1.41
Female 79 72 1.10 0.87-1.37
By race White 78 78 1.00 0.79-1.24
Black 8 8 1.04 0.45-2.05
Hispanic 10 9 1.10 0.53-2.02
Other 14 8 1.74 0.95-2.91
*Indicates statistically significant difference.
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roid carcinoma at our institution versus that expected
from NHANES data (Table 3). For patients of all ages
with newly evaluated papillary thyroid carcinoma at our
institution, there was a non-significant trend for a higher
rate of diabetes (odds ratio 1.07, CI 0.88 - 1.28). For pa-
tients aged 0 – 44 years with newly evaluated papillary
thyroid carcinoma at our institution, however, there was
a statistically and clinically significant increase in the
prevalence of diabetes, with more than twice the ex-
pected number of patients with diabetes (ratio 2.32, CI
1.37 - 3.66). There was no significant difference when
subgroup analysis was performed with stratification






0-44 18 (3%) <0.0001
45-64 61 (11%)Risk factors for diabetes
The characteristics of patients with diabetes versus those
without diabetes were compared (Table 4). Age was
found to be a significant risk factor for diabetes, withTable 2 Characteristics of the diabetes diagnosis at the
time of initial thyroid cancer evaluation
Diabetes (n = 110)
Type of diabetes Type 1 6 (6%)
Type 2 101 (92%)
Secondary to steroid use 2 (2%)
Unknown 1
On insulin No 84 (76%)
Yes 26 (24%)patients aged 44 years or younger less likely to have dia-
betes, and an increasing frequency of diabetes with each
subsequent age group. Gender was not a risk factor for
diabetes, but race was a significant risk factor, with white
race being protective for diabetes compared to other
groups: 7% in whites, 16% in blacks, 14% in Hispanics.Discussion
Diabetes is an epidemic disease with extensive ramifica-
tions on various organ systems. The long-term compli-
cations of diabetes comprise not only the classically
cited ones, including retinopathy, nephropathy, neur-
opathy, coronary heart disease, stroke, and peripheral
vascular disease, but also cancer. Patients with diabetes65-74 23 (16%)
75+ 8 (17%)
Sex Male 31 (9%) 0.65
Female 79 (8%)
Race White 78 (7%) 0.003
Black 8 (16%)
Hispanic 10 (14%)
Other ** 14 (15%)
*P-value calculated using age as a continuous variable.
**Asian and other race categories were combined to match how race is
collected in NHANES.
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bladder, liver, colorectum, and pancreas [1].
Previous studies regarding the risk of thyroid cancer in
patients with diabetes have yielded conflicting data. A
case–control study showed a 4-fold increased prevalence
of diabetes among 110 patients with anaplastic thyroid
cancer [4]. One cohort study with 585 thyroid cancer
cases showed an increased prevalence of thyroid cancer
among women with diabetes but not among men with
diabetes [5], whereas two other cohort studies, with
1053 [6] and 943 [7] thyroid cancer cases respectively,
showed no significant increase in the prevalence of thy-
roid cancer among patients with diabetes.
Using a database of more than 1500 patients with thy-
roid cancer and an age-, gender-, and race-matched ana-
lysis, we compared the prevalence of diabetes in patients
with newly evaluated papillary thyroid cancer with that
expected based on NHANES data. For patients of all
ages, we found a non-significant increase in the preva-
lence in diabetes. For patients 44 years of age or youn-
ger, we found a significant increase in the prevalence of
diabetes that was more than twice expected.
This is the first study to focus on the prevalence of
diabetes exclusively in patients with papillary thyroid
carcinoma and the first study to demonstrate an age as-
sociation between diabetes and thyroid cancer. Since the
cancer was newly evaluated for inclusion in the study,
the diagnosis of diabetes preceded the diagnosis of thy-
roid cancer, suggesting that diabetes was a risk factor for
the papillary thyroid carcinoma in the subset of patients
44 years of age or younger. It is possible that the diagno-
sis of papillary thyroid carcinoma led to a diagnosis of
diabetes by connecting young people to the healthcare
system, thus accounting for a higher prevalence of dia-
betes compared with their peers. Akker et al. recently
demonstrated an increase in insulin resistance in pa-
tients with differentiated thyroid cancer [11], however,
consistent with the hypothesis that diabetes increases
the risk of thyroid cancer through hyperinsulinemia and
activation of the insulin receptor or the insulin-like
growth factor-I receptor. Recent evidence suggests that
activation of the mitogen-activated protein (MAP) kin-
ase signaling pathway is important in the development
of insulin resistance, type 2 diabetes, and cancer [12,13].
One limitation of our study is that it is retrospective,
which exposes the study to bias, including selection bias
of patients. Another limitation of our study is that our
study population comprises newly evaluated thyroid can-
cer patients at a single, tertiary care referral institution
over a four year period. Furthermore, our study popula-
tion is predominantly Caucasian (83%). Finally, as there
is no longitudinal follow-up of patients, there is no
mechanism to determine the prevalence of diabetes after
the diagnosis of thyroid cancer.Conclusions
Our study suggests that diabetes is a risk factor for pap-
illary thyroid carcinoma in patients 44 years of age or
younger. Further investigation is needed regarding the
relationship between diabetes and thyroid cancer and
their possible shared pathophysiology.
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